|
|
ASH 2018 <strong>Updated Phase 1 Data of Indoximod Plus Standard Induction Chemotherapy in Newly Diagnosed AML </strong> |
|
|
|
SITC 2018 <strong>Phase 1 Pharmacokinetic Data for NLG802 Prodrug</strong> |
|
|
|
SITC 2018 <strong>Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Advanced Melanoma</strong> |
|
|
|
SITC 2018 <strong>Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Metastatic Pancreatic Cancer</strong> |
|
|
|
ISPNO 2018 <strong>Updated Phase 1 Data for Indoximod Plus Radio-Immunotherapy for Pediatric Patients with Newly Diagnosed DIPG</strong> |
|
|
|
ASCO 2018 <strong>Phase 2 Results for Indoximod Plus Pembrolizumab in Advanced Melanoma</strong> |
|
|
|
ASCO 2018 <strong>Phase 2 Results for Indoximod Plus Gemcitabine/nab-Paclitaxel in Metastatic Pancreatic Cancer</strong> |
|
|
|
AACR 2018 <strong>Indoximod Modulates AhR-driven Transcription of Genes That Control Immune Function</strong> |
|
|
|
AACR 2018 <strong>Phase 1 Study of Indoximod Plus Radiation & Chemotherapy for Pediatric Patients with DIPG and Other Brain Tumors</strong> |
|
|
|
SNO 2017 <strong>Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer</strong> |
|
|
|
TCH 2017 <strong>Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer</strong> |
|
|
|
CIC 2017 <strong>Interim Phase 2 of Indoximod plus Pembrolizumab in Advanced Melanoma</strong> |
|
|
|
EHA 2017 <strong>Phase I Indoximod plus Idarubicin & Cytarabine for Newly Diagnosed Acute Myeloid Leukemia</strong> |
|
|
|
ASCO 2017 <strong>Phase II Double-blind study of Metastatic Castration-resistant Prostate Cancer</strong> |
|
|
|
AACR Plenary 2017 <strong>Indoximod plus Keytruda (pembrolizumab) Phase II Interim in Advanced Melanoma</strong> |
|
|
|
AACR 2017 <strong>NLG802 Prodrug Poster Presentation</strong> |
|
|
|
SNO 2016 <strong>Indoximod + Temozolomide Brain Tumor Trial</strong> |
|
|
|
ASCO 2016 <strong>Pancreas indoximod</strong> |
|
|
|
ASCO 2016 <strong>Melanoma indoximod</strong> |
|
|
|
ASCO GI 2016 <strong>Indoleamine Phase II Trial</strong> |
|
|
|
ASCO GI <strong>Indoximod + Gemcitabine/nab-Paclitaxel</strong> |
|
|
|
SABCS 2015 <strong>Indoximod Phase II Metastatic Breast Cancer Trial</strong> |
|
|
|
SITC 2015 <strong>GDC-0919 + PD-L1</strong> |
|
|
|
ECCO-ESMO 2015 <strong>Indoximod + Ipilimumab Melanoma Trial</strong> |
|
|
|
ESMO 2015 <strong>GDC-0919</strong> |
|
|
|
ASCO 2015 <strong>Indoximod and Temozolomide</strong> |
|
|
|
IUMS <strong>Highly efficacious influenza vaccination using HyperAcute® Technology</strong> |
|
|
|
ASCO 2014 <strong>Algenpantucel-L</strong> |
|
|
|
ASCO 2014 <strong>Sipuleucel-T +- Indoximod</strong> |
|
|
|
ASCO 2014 <strong>Tergenpumatucel-L vs. Docetaxel</strong> |
|
|
|
ASCO 2014 <strong>Docetaxel + Indoximod</strong> |
|
|
|
ASCO 2014 <strong>Ad.p53 + Indoximod</strong> |
|
|
|
ASCO 2014 <strong>NLG919</strong> |
|
|
|
ASCO 2014 <strong>Indoximod + Temozolomide</strong> |
|
|
|
ASCO 2014 <strong>Ipilimumab +- Dorgenmeltucel-L</strong> |
|
